Improvements in target validation rates by automating and streamlining antibody production
Case study: Adopting the BioXp™ system compresses design-build-test cycle times and increases pipeline by 25% for one biopharmaceutical company developing an antibody-based therapeutic
Engineered T cells have been used successfully to treat several leukemias and solid tumors. However, building and screening engineered T cell receptors is time-consuming and labor-intensive. Learn how a biopharmaceutical company transitioned from a traditional method of building expression constructs for a chimeric antigen receptors (CAR) to an automated method using the BioXp™ system. The BioXp™ system is the world’s first and only commercially available push-button automated platform for on-demand synthesis of DNA fragments, libraries, and more. The traditional method relied on manual processes for DNA fragment synthesis, cloning, and tracking the reactions. The large number of candidates required for screening made this method prone to human error, cumbersome, and complicated. Adopting the BioXp™ system streamlined the building of expression constructs, eliminating several manual processes from the workflow, and accelerated the identification of lead candidates.
